Diagnostic and Testing Equipment Bi-Weekly Industry Events & M&A Update — September 14–28, 2026

Read the report

SlidesScroll

1 of 7

←→Full screen

BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE

HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › DIAGNOSTIC AND TESTING EQUIPMENT

Consumable Annuities Earn the Bid While Placement Stories Wait

This update covers the two-week period September 14–28, 2026 in diagnostic and testing equipment: who moved, what companies announced, and the one agreed transaction.

September 14–28, 2026

Prepared by NeuraCap AI · Confidential

Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28

Diagnostic and Testing Equipment Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice

Sources & methodology

1

← Previous

1 / 7 · HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › DIAGNOSTIC AND TESTING EQUIPMENT

Next →

What each page shows

The analyst’s walkthrough of the deck, page by page.

1. 01
   BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE

   HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › DIAGNOSTIC AND TESTING EQUIPMENT

   Cover page introducing the Diagnostic and Testing Equipment bi-weekly industry events and M&A update for September 14–28, 2026.

   We open this bi-weekly update on diagnostic and testing equipment, covering September 14–28, 2026. Across the following pages we answer what changed, who moved and most likely why, what transacted, and what it means for owners, acquirers and advisors.

   Everything on this page

   BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › DIAGNOSTIC AND TESTING EQUIPMENT Consumable Annuities Earn the Bid While Placement Stories Wait This update covers the two-week period September 14–28, 2026 in diagnostic and testing equipment: who moved, what companies announced, and the one agreed transaction. September 14–28, 2026 Prepared by NeuraCap AI · Confidential Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28 Diagnostic and Testing Equipment Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 1

2. 02
   THE BI-WEEKLY BOTTOM LINE

   Buyers Reward the Recurring Side of the Menu

   Bottom-line summary showing 18 of 25 covered names rose with a median move of +3.8% against the S&P 500's +0.8%.

   We start with the bottom line: 18 of the 25 names we cover rose over the period, and the median move came in at +3.8%, comfortably ahead of the S&P 500's +0.8%. Illumina led the group at +30.6%, tied to a growth and outlook story rather than a single headline event. The period's one agreed transaction, IDEXX Laboratories' acquisition of CoVet, added workflow intelligence around an installed veterinary base. So what: the market is paying up for recurring, consumable-driven businesses, and that is the lens we carry through the rest of this update.

   Everything on this page

   THE BI-WEEKLY BOTTOM LINE Buyers Reward the Recurring Side of the Menu The two-week period in one page · 25 covered names, close-to-close · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Driver attributions use calibrated language and are NeuraCap reads of the recorded evidence. Diagnostic and Testing Equipment Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 2 1 18 of 25 Covered Names Rose; The Median Move Was +3.8% The set ran ahead of the S&P 500, which returned +0.8% over the window. Direction was broad rather than driven by one or two names. 2 Illumina Led the Set on a Growth and Outlook Story Illumina, Inc. (ILMN) rose +30.6%, with its biggest single day of +7.3% on Sep 24. Coverage that day tied a 94.9% year-to-date rally to sequencing growth, clinical adoption and a raised 2026 outlook. 3 The Period's One Agreed Deal Bought Workflow Around an Installed Base IDEXX Laboratories, Inc. (IDXX) announced the acquisition of CoVet, adding veterinary workflow intelligence. The trailing record carries 40 precedent transactions at a median of 8.8x EV/EBITDA. 4 The Window Sits Comfortably with the Standing View of the Sector NeuraCap's standing lens marks the sector at 21.1x CY2027E EV/EBITDA, with the Premium tier at a 48.5x median and the Discount tier at 9.0x. Repligen Corporation (RGEN), a Premium-tier name, was among the period's largest gainers. +30.6% Best mover — Illumina, Inc. (ILMN) worst: SSII -14.7% · 18 up / 7 down of 25 covered +3.8% Sector median two-week return vs S&P 500 +0.8% 1 Transaction agreed in the two-week period from company announcements; not yet in the precedent record 1 Company filings in the window 8-K events read for driver attribution

3. 03
   PUBLIC MARKET MOVERS

   One Mover with a Stated Story, and Three the Record Does Not Explain

   Public market movers page identifying Illumina's stated growth story and three moves the recorded evidence does not explain.

   We turn next to the individual movers, measured close-to-close against a sector median of +3.8% and a materiality bar of ±9.4%. Illumina rose +30.6%, with a +7.3% single-day move on Sep 24 that coverage tied to sequencing growth, clinical adoption and a raised 2026 outlook. Three other names moved by a magnitude the recorded filings and headlines do not explain, and we say so plainly rather than force an attribution. So what: distinguishing a stated story from an unexplained move tells owners and advisors where the market has already priced in information, and where it may still be digesting something not yet public.

   Everything on this page

   PUBLIC MARKET MOVERS One Mover with a Stated Story, and Three the Record Does Not Explain Bi-Weekly moves, close-to-close · September 14–28, 2026 · sector median +3.8% · S&P 500 +0.8% · materiality bar ±9.4% (sector-relative) Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Attribution links each move only to filings and headlines recorded in the window; where no driver is recorded, the page says so. Calibrated language throughout — NeuraCap reads, not asserted causation. Diagnostic and Testing Equipment Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 3 Bi-Weekly return per company · teal above zero, amber below · sector median +3.8% Illumina, Inc. (ILMN) +30.6% The move appears to reflect the growth story set out in Sep 24 coverage of the company's 94.9% year-to-date rally: sequencing growth, clinical adoption and a raised 2026 outlook despite China headwinds. Menu breadth and clinical adoption on a placed platform still set the mark for the sector's growth names. COMPANY-SPECIFIC OraSure Technologies, Inc. (OSUR) +17.2% No notable in-window news was identified that clearly explains the move. At +17.2%, OraSure Technologies, Inc. (OSUR) ran ahead of the set's +3.8% median. Where the company record is quiet, the set's median is the only clean reference point. UNEXPLAINED Repligen Corporation (RGEN) +15.5% No notable in-window news was identified that clearly explains the move. The +15.5% gain was well above the set's +3.8% median. Repligen is a Premium-tier name, and the consumables side of this sector carries the higher mark. UNEXPLAINED SS Innovations International, Inc. (SSII) -14.7% No notable in-window news was identified that clearly explains the move. At -14.7%, SS Innovations International, Inc. (SSII) sat furthest from the set's +3.8% median. Placement-led device stories move on their own timetable, with little help from the set's direction. UNEXPLAINED

4. 04
   MAJOR NEWS & INDUSTRY CATALYSTS

   What Companies Actually Did: Menu, Partnerships and a Settled Claim

   Major news page covering menu additions, partnerships and a settled claim announced during the period.

   This page walks through what companies actually did over the two weeks, including Waters' FDA-cleared at-home HPV screening tool developed with Everlywell, the launch of the A7 analyzer, and Senseonics' integration of Eversense 365 with the iLet Bionic Pancreas. Each item links to its underlying filing or article, and each 'why it matters' line is our read of the recorded evidence, not the company's own framing. So what: these announcements show the sector moving deeper into at-home and connected-care testing, the same theme that showed up in the price moves on the prior page.

   Everything on this page

   MAJOR NEWS & INDUSTRY CATALYSTS What Companies Actually Did: Menu, Partnerships and a Settled Claim The two-week period's highest-impact events · titles link to the underlying filing or article · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. "Why it matters" lines are NeuraCap reads; each event links to its source. Sources are admitted in a fixed reliability order (SEC filings, press releases, established outlets); video and social platforms are never used. Diagnostic and Testing Equipment Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 4 Sep 16 · NEWS · Business Wire IDEXX acquires CoVetAI to advance veterinary workflow intelligence Veterinary is one of the sector's more defensible non-clinical annuities, and a Core-tier name is buying workflow rather than menu. Informatics attached to an installed base is being bought, not built. Sep 16 · NEWS · GlobeNewsWire Philips-led projects win ITEA awards for AI-enabled healthcare work Recognition for connected healthcare ecosystems and fiber-optic sensing shows where Koninklijke Philips N.V. (PHG) is putting development effort. Workflow and informatics integration is where installed-base defence gets built. Sep 16 · NEWS · Business Wire Everlywell partners with Waters on an FDA-cleared at-home HPV screening tool This is testing moving out of the central lab toward the home, with a cleared tool behind it. For Waters Corporation (WAT), a Core-tier name, home collection widens the volume a placed platform can pull through. At-home collection extends the central-lab menu rather than replacing it. Sep 15 · NEWS · Business Wire Neogen sets its first-quarter earnings release date for October 6 This is timing rather than news about the business: it fixes when the next operating read from Neogen Corporation (NEOG), a Core-tier name, reaches the market. The next scheduled report gives the set a check on recurring revenue quality. Sep 14 · NEWS · GlobeNewsWire Senseonics partners with Beta Bionics to integrate Eversense 365 with the iLet pump Pairing a year-long continuous glucose sensor with automated insulin delivery is a workflow move aimed at an existing user community. The NeuraCap read: in this sector, integration arrangements often precede ownership. Distribution and integration deals are the usual first step toward a transaction. Sep 14 · NEWS · PRNewsWire Waters launches the BD FACSDiscover A7 cell analyzer for spectral flow cytometry A commercial launch is a placement event with a consumable and service stream behind it, and standardised instrument-to-instrument performance is what lowers a lab's objection to switching. Launch cadence on one platform is how menu expansion shows up in revenue.

5. 05
   M&A & STRATEGIC ACTIVITY

   IDEXX Buys the Workflow Layer Sitting Around Its Veterinary Base

   M&A page detailing IDEXX Laboratories' agreed acquisition of CoVet against a precedent record of 40 deals at a median 8.8x EV/EBITDA.

   The period's one agreed transaction is IDEXX Laboratories' acquisition of CoVet, adding workflow intelligence around its existing veterinary installed base. We size that deal against a trailing record of 40 precedent transactions, which carry a median of 8.8x EV/LTM EBITDA. The multiple sits within a range this sector has supported before, and the deal logic reads as installed-base extension rather than new-market entry. So what: for acquirers, this is a template for buying workflow adjacent to a base you already own, at a multiple the market has already validated.

   Everything on this page

   M&A & STRATEGIC ACTIVITY IDEXX Buys the Workflow Layer Sitting Around Its Veterinary Base September 14–28, 2026 · 1 agreed by company announcement · precedent transactions: 40 recorded deals · median 8.8x EV/LTM EBITDA Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Deal multiples are LTM at announcement where disclosed; "why the deal happened" is a NeuraCap read of the recorded evidence. No old transactions are re-presented as news. Diagnostic and Testing Equipment Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 5 AGREED IN THE PERIOD — FROM COMPANY ANNOUNCEMENTS Sep 17 · IDEXX Laboratories, Inc. (IDXX) IDEXX Laboratories (IDXX) acquires CoVet, adding workflow intelligence to its veterinary business The period's one announced transaction has a strategic buying software around a base it already serves. The NeuraCap read: appetite is pointing at recurring, non-clinical end markets rather than pre-reimbursement clinical assets. Terms and multiples enter the precedent record once the filing is processed; the reference set alongside is unchanged. 40 Recorded precedent transactions the reference set buyers and sellers price against 8.8x Precedent median EV/LTM EBITDA LTM at announcement, where disclosed

6. 06
   WHAT IT MEANS

   Where the Period Leaves Owners, Buyers and Advisors

   Implications page translating the period's evidence into observations for owners, acquirers and advisors.

   We close by translating the period for the people who act on it. Owners are seeing recurring-mix businesses rewarded: 18 of 25 covered names rose, with a median move of +3.8% against the S&P 500's +0.8%. Acquirers now have one new agreed transaction, IDEXX's purchase of CoVet, to weigh against 40 precedent deals at a median 8.8x EV/EBITDA. So what: for advisors, the period's evidence points one way — lead conversations with the recurring, connected-care annuity, not the one-time placement story.

   Everything on this page

   WHAT IT MEANS Where the Period Leaves Owners, Buyers and Advisors The two-week period translated for the people who act on it · NeuraCap view · observations, not recommendations Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. This page is analytical interpretation drawn from the two-week period's recorded evidence. It is not investment advice. Diagnostic and Testing Equipment Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 6 Sector study 2026-09-28 EV / EBITDA (CY2027E) median 21.1x 26 companies in the study 3 valuation tiers Standing thesis: Diagnostic and testing equipment prices consumables annuities apart from placement-led devices FOR OWNERS & OPERATORS Recurring Mix Is Doing the Work Companies in the space traded higher: 18 of 25 covered names rose and the median move was +3.8%, against +0.8% for the S&P 500. FOR ACQUIRERS One New Record, and a Reference Set That Moved Up The period adds one announced transaction, IDEXX Laboratories' acquisition of CoVet, to a trailing record of 40 precedent transactions at a median of 8.8x EV/EBITDA. FOR ADVISORS Lead with the Annuity, Not the Placement Year The period's evidence runs one way: IDEXX buying veterinary workflow, Waters behind an FDA-cleared at-home HPV screening tool with Everlywell and launching the A7 analyzer, and Senseonics integrating Eversense 365 with the iLet Bionic Pancreas.

7. 07
   SOURCES & METHODOLOGY

   Sources, Methodology and Important Notice

   Sources and methodology page explaining how figures, attributions and the deal record are built and sourced.

   Every figure in this update links back to the record it was taken from — SEC filings, company press releases and established outlets, with a fixed reliability order and no video or social sourcing. Attribution language is calibrated: where the record shows a driver, we say so; where it doesn't, we say that too. So what: this page is your audit trail, letting you or your team verify any number before acting on it.

   Everything on this page

   SOURCES & METHODOLOGY Sources, Methodology and Important Notice How this bi-weekly update is built and what each kind of statement rests on · September 14–28, 2026 · market data through 2026-09-28 Every figure in this update links to the record it was taken from; the publishers and filings drawn on for the period are listed above. Diagnostic and Testing Equipment Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice 7 OBSERVED DATA Bi-Weekly stock moves are computed close-to-close over the stated window from the platform’s price series. Deal records, values and multiples come from the platform’s transaction record (SEC 8-K extractions) exactly as recorded; each figure links to its citation. Treasury rates come from the platform’s Treasury series and are shown only when the 10-year moved at least ten basis points over the window (it did not in this window, so no rate figures appear). UNIVERSE QUALITY The update universe is the platform’s approved company set for this sector, subject to a $100M market-cap floor so small, loosely related names cannot dominate the statistics. 1 name below the floor was excluded from movers and statistics for this window. EVENTS & NEWS Company events are in-window 8-K filings; news items are publisher-sourced headlines fetched for the window (and any externally supplied items, marked as such). Operational and strategic developments (deals, partnerships, launches, expansion, guidance, leadership, regulatory outcomes) are shown first; capital-return mechanics and conference appearances are limited to one each. Every event links to its source. The deck never asserts an event that has no linked record. SOURCE HIERARCHY News is admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then transaction documents, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron’s and peers). Video and social platforms — including YouTube — are never used as sources. DRIVER ATTRIBUTION A stock move is linked to an event only when the event falls inside the window, and only in calibrated language ("the move appears to reflect…", "shares moved following…"). Where no driver is recorded, the page says so and compares the move to the sector median instead. ANALYTICAL INTERPRETATION "Why it matters", "why the deal happened" and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, and are labeled as such. INHERITED CONTEXT The standing sector view (thesis, valuation lens, sector median and tiering) is inherited from the NeuraCap sector study run_20260929T154913Z_524_prod (market data as of 2026-09-28) — distilled, never re-derived. That report’s own sources page governs its content; this update reads the period against it. IMPORTANT NOTICE This report is informational only. It is not investment advice, not a recommendation to buy or sell any security, and not an offer of any kind. Readers should perform their own diligence before acting on anything described here. Linked sources this two-week period: businesswire.com · globenewswire.com · prnewswire.com · sec.gov

More coverage in Health Care

• Sector Report · Sep 28, 2026Diagnostic and Testing Equipment Sector Outlook — September 2026
• Sector Report · Sep 28, 2026Medical Devices Sector Outlook — September 2026
• Bi-Weekly Update · Sep 28, 2026Medical Devices Bi-Weekly Industry Events & M&A Update — September 14–28, 2026
• Sector Report · Sep 28, 2026Managed Health Care Sector Outlook — September 2026